AzTrials
AzTrials

Disorders of ConsciousnessBlink-DoCNCT06323031

Spontaneous Eye Blinking in Disorders of Consciousness

An observational study of Disorders of Consciousness, run by Fondazione Don Carlo Gnocchi ETS at 8 sites in 4 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Differential diagnosis between Unresponsive Wakefulness Syndrome (UWS) and Minimally Conscious State (MCS) is complicated due to severe cognitive and/or sensorimotor deficits in these patients. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Disorders of Consciousness
How many people
70 participants
Where
8 sitesin 4 countries
Study dates
8 May 2025to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients in UWS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).

Who may be able to join

  • clinical diagnosis of DoC (UWS, MCS minus, MCS plus) following repeated clinical evaluation (at least four CRS-R in a week)
  • age ≥ 18 years
  • time post-onset ≤6 months
  • Previous sABI of any etiology (traumatic, vascular, anoxic, mixed, etc.)
  • Negative anamnesis for neurological or psychiatric disorders.

Who cannot join

  • unstable clinical conditions (e.g. respiratory failure, fever, status epilepticus, etc.);
  • ophthalmic diseases, or clinically detected peripheral damage in eyelid motility (e.g. orbital fracture);
  • intake of sedative drugs in the preceding 24 hours;
  • additional brain event following admission (e.g., stroke).

Trial locations and contacts

8 sites in 4 countries. Contact the study team or a site near you to ask about taking part.

Alfonso Magliacano, PhD contact

3387389414 ext. 39

amagliacano@dongnocchi.it

8 sites in 4 countries

Italy4 sites, 4 recruiting
  • Unità Gravi Cerebrolesioni - Dipartimento Neuroscienze - Azienda Ospedaliera - Universitaria Ferrara

    Ferrara, Italy, 44124

    Susanna Lavezzi, s.lavezzi@ospfe.it

    Susanna Lavezzi

    Recruiting
  • IRCCS Fondazione Don Gnocchi ONLUS

    Florence, Italy, 50143

    Bahia Hakiki, PhD, bhakiki@dongnocchi.it

    Bahia Hakiki, PhD

    Recruiting
  • IRCCS Santa Maria Nascente Fondazione Don Gnocchi ONLUS

    Milan, Italy, 20148

    Angela Comanducci, PhD, acomanducci@dongnocchi.it

    Angela Comanducci, PhD

    Recruiting
  • Polo Specialistico Riabilitativo Fondazione Don Carlo Gnocchi ONLUS

    Sant'Angelo dei Lombardi, AV, 83054

    Anna Estraneo, PhD, 3396418648 ext. 39, aestraneo@dongnocchi.it

    Alfonso Magliacano, PhD, 3387389414 ext. 39, amagliacano@dongnocchi.it

    Recruiting

Other trials in Italy

Germany2 sites, 2 recruiting
  • Therapiezentrum Burgau

    Burgau, Germany, 89331

    Andreas Bender, MD, a.bender@therapiezentrum-burgau.de

    Andreas Bender, MD

    Recruiting
  • Dipartimento di Neurologia, LMU Hospital, LMU Munich

    Munich, Germany, 81377

    Konstantinos Dimitriadis, konstantin.dimitriadis@med.unimuenchen.de

    Konstantinos Dimitriadis

    Recruiting

Other trials in Germany

Belgium1 site, 1 recruiting
  • Coma Science Group, GIGA-Consciousness, University of Liege

    Liège, Belgium, 4000

    Olivia Gosseries, PhD, ogosseries@uliege.be

    Olivia Gosseries, PhD

    Not yet recruiting

Other trials in Belgium

Spain1 site, 1 recruiting
  • Instituto de Rehabilitación Neurológica IRENEA

    Valencia, Spain, 46007

    Enrique Noé, MD, enoe@comv.es

    Enrique Noé, MD

    Recruiting

Other trials in Spain

About this study

Official title: Spontaneous Eye Blinking as a Diagnostic and Prognostic Marker in Patients With Disorders of Consciousness After Severe Acquired Brain Injury

Differential diagnosis between Unresponsive Wakefulness Syndrome (UWS) and Minimally Conscious State (MCS) is complicated due to severe cognitive and/or sensorimotor deficits in these patients. In this study the investigators aimed at exploring the diagnostic and prognostic validity of spontaneous eye blinking parameters (rate, amplitude, duration, variability) in a sample of patients with Disorders of Consciousness (DoC).

This is a multi-center prospective observational study conducted in patients with Severe Acquired Brain Injury (sABI) and DoC admitted to 8 European participating centers, with clinical data collection not deviating from routine practice. The study is non-commercial and will have a maximum total duration of 24 months.

Read the detailed description

Observational, multicenter, longitudinal study. In this study, all patients admitted to the nine participating centers with diagnosis of DoC, and meeting the inclusion/exclusion criteria, will be enrolled.

The admission of a patient to the research program is subject to the signing of an informed consent by the legal representative/primary caregiver of the patient. The representative will be informed about the study and its objectives, and an informational sheet will be provided.

Population All patients with DoC after sABI consecutively admitted to participating centers who meet the inclusion/exclusion criteria (see below).

Sample size On the basis of the effect size found in a previous study regarding the diagnostic value of eye blink rate (d=0.68), it is planned to enroll 58 patients with DoC (power=0.8; α=0.05) + an additional 20% to cope with possible drop-outs, for a total of 70 patients (23 in UWS, 23 in MCS minus; 23 in MCS plus; about 9 patients per center). For the secondary outcomes (i.e., diagnostic and prognostic value of further blink features) there is no previous data in the literature. In addition, a sample of 23 healthy individuals, balanced in terms of sex and age with the patient sample, will be enrolled as a reference group.

Data collection procedure Within two weeks from study entry, patients will undergo two 20-minute resting electroencephalogram-electrooculogram (EEG-EOG) examinations, separated by 24 hours. Sessions will take place, following standard nursing procedures, between 10:00 AM and 5:00 PM, a time window minimally influenced by circadian peaks of drowsiness in patients with DoC, and a period during which it is believed that EBR is stable in healthy individuals.

The EEG-EOG recording will be conducted at the patient's bedside or, if possible, on their wheelchair, with the patient awake (i.e., eyes open), maintaining a quiet and dimly lit environment. If the patient's arousal level is insufficient, the Coma Recovery Scale-Revised (CRS-R) arousal facilitation protocol will be administered; if the patient continues to keep their eyes closed, the recording session will be postponed to the next available day. During each session, the experimenter is positioned beside the patient, out of her/his visual field. Blinks will be detected in the EOG and defined as a sharp positive peak followed by a negative deflection within a time window of less than 400 ms. To assess the level of consciousness at the time of the EEG-EOG recordings, a CRS-R will be administered at the end of each session. To prevent the patient's awareness of the blink recording from affecting their blink rate, the patient is not informed about the blink recording during the EEG-EOG session but is simply encouraged to remain relaxed with eyes open and not to move. This procedure is carried out independently of the patient's clinical diagnosis. A follow-up assessment is planned at 6 months from T0 (T1).

The healthy volunteers will also perform two resting EEG-EOG examinations, each lasting 20 min, 24 h apart.

EEG will be recorded by at least 19 electrodes placed on the patients' scalp according to the international 10-20 system (Fp1, Fp2, F7, F8, F3, F4, C3, C4, T3, T4, P3, P4, T5, T6, O1, O2, Fz, Cz, Pz) + vertical EOG electrodes, referenced to the vertex. Impedance will be kept below 5 kΩ for electrodes covering the cortex as well as for EOG electrodes. Data will be sampled at a 1000-Hz rate and band pass filtered between 0.1 Hz and 30 Hz; a notch filter will be used to eliminate frequencies around 50 Hz for online visualization. If the EEG recording in a session presents a considerable number of artefacts, the acquisition will be repeated within the next available day.

Enrollment duration: 12 months Study duration: about 24 months.

Statistical plan Patient characteristics at study entry will be compared between the diagnostic groups (UWS, MCS minus, MCS plus) through parametric or non-parametric univariate analyses, as deemed appropriate after verification of data distribution. Similarly, univariate analyses will be performed to compare eye blink rate (EBR) and additional blink features between diagnostic groups.

Univariate within-subject analyses will be performed to compare EBR and additional blink features across time.

In addition, correlation analyses will be performed to verify the existence of a relationship between blink features and level of consciousness as measured by the total score of the CRS-R. If so, logistic regression models will be implemented with blink features and demographic and anamnestic variables as predictors, and outcome as dependent variable. The results will be considered statistically significant if p<05.

Keywords
Disorders of Consciousness, blinking, diagnosis, prognosis, rehabilitation
Medical subject headings
Consciousness Disorders, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06323031
Study groupRoleWhat they receive
Patients with DoC consecutively admitted to participating units and met the inclusion criteriaPatients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Diagnosis

    Clinical diagnosis as assessed by the Coma Recovery Scale-Revised (min. - max- score = 0-23, with higher scores indicating a higher level of consciousness)

    Measured: 6 months from enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Mar 2024
  2. Study start8 May 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06323031
Sponsor's protocol ID
Blink-DoC
Acronym
Blink-DoC
Status last verified
Jul 2026
First submitted
14 Mar 2024
Last updated
13 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD will be shared upon reasonable request.

Publications

  • Wislowska M, Del Giudice R, Lechinger J, Wielek T, Heib DPJ, Pitiot A, Pichler G, Michitsch G, Donis J, Schabus M. Night and day variations of sleep in patients with disorders of consciousness. Sci Rep. 2017 Mar 21;7(1):266. doi: 10.1038/s41598-017-00323-4.

    PubMed 28325926
  • Barbato G, Ficca G, Muscettola G, Fichele M, Beatrice M, Rinaldi F. Diurnal variation in spontaneous eye-blink rate. Psychiatry Res. 2000 Mar 6;93(2):145-51. doi: 10.1016/s0165-1781(00)00108-6.

    PubMed 10725531
  • Magliacano A, Rosenfelder M, Hieber N, Bender A, Estraneo A, Trojano L. Spontaneous eye blinking as a diagnostic marker in prolonged disorders of consciousness. Sci Rep. 2021 Nov 17;11(1):22393. doi: 10.1038/s41598-021-01858-3.

    PubMed 34789832

Questions about this trial

What is this clinical trial studying?

An observational study of Disorders of Consciousness, run by Fondazione Don Carlo Gnocchi ETS at 8 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in Italy, Germany, Belgium, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anna Estraneo, MD (3396418648 ext. 39, aestraneo@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Diagnosis (time frame: 6 months from enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06323031, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in